• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Piper Sandler reiterated coverage on Seagen with a new price target

    2/10/22 10:06:44 AM ET
    $SGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGEN alert in real time by email
    Piper Sandler reiterated coverage of Seagen with a rating of Neutral and set a new price target of $150.00 from $165.00 previously
    Get the next $SGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGEN

    DatePrice TargetRatingAnalyst
    2/16/2023$140.00 → $175.00In-line → Outperform
    Evercore ISI
    2/16/2023$155.00 → $175.00Outperform → Strong Buy
    Raymond James
    2/6/2023$162.00 → $141.00Outperform → Market Perform
    SVB Securities
    11/21/2022$135.00Hold
    Truist
    10/11/2022$177.00 → $178.00Market Perform → Outperform
    BMO Capital Markets
    6/29/2022$220.00Outperform
    Raymond James
    6/24/2022$169.00Market Perform
    BMO Capital Markets
    2/16/2022$201.00 → $142.00Market Outperform
    JMP Securities
    More analyst ratings

    $SGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Seagen upgraded by Evercore ISI with a new price target

      Evercore ISI upgraded Seagen from In-line to Outperform and set a new price target of $175.00 from $140.00 previously

      2/16/23 7:26:41 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seagen upgraded by Raymond James with a new price target

      Raymond James upgraded Seagen from Outperform to Strong Buy and set a new price target of $175.00 from $155.00 previously

      2/16/23 6:40:35 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Seagen downgraded by SVB Securities with a new price target

      SVB Securities downgraded Seagen from Outperform to Market Perform and set a new price target of $141.00 from $162.00 previously

      2/6/23 7:35:55 AM ET
      $SGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care